EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Review on Approved and Inprogress COVID-19 Vaccines

Amir Farnudian-Habibi iD, Mobina Mirjani, Vahideh Montazer, Shima Aliebrahimi, Iman Katouzian, Saeed Abdolhosseini, Ali Rahmani, Hossein Keyvani, Seyed Nasser Ostad iD, Mazda Rad-Malekshahi iD

Iranian Journal of Pharmaceutical Research · 24.01.2022 · 21 (1)

DOI: 10.5812/ijpr.124228 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 24.01.2022. Verfasst von Amir Farnudian-Habibi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Biomaterials, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

: The last generation of Coronavirus named COVID-19 is responsible for the recent worldwide outbreak. Concerning the widespread and quick predominance, there is a critical requirement for designing appropriate vaccines to surmount this grave problem. Correspondingly, in this revision, COVID-19 vaccines (which are being developed until March 29th, 2021) are classified into specific and non-specific categories. Specific vaccines comprise genetic-based vaccines (mRNA, DNA), vector-based, protein/recombinant protein vaccines, inactivated viruses, live-attenuated vaccines, and novel strategies including microneedle arrays (MNAs), and nanoparticles vaccines. Moreover, specific vaccines such as BCG, MRR, and a few other vaccines are considered Non-specific. What is more, according to the significance of Bioinformatic sciences in the cutting-edge vaccine design and rapid outbreak of COVID-19, herein, Bioinformatic principles including reverse vaccinology, epitopes prediction/selection and, their further applications in the design of vaccines are discussed. Last but not least, safety, challenges, advantages, and future prospects of COVID-19 vaccines are highlighted.

Schlagwörter

Stichwörter der Autor:innen

BioinformaticCOVID-19Epitope PredictionReverse VaccinologymRNA Vaccine

Autor:innen und Institutionen

  • Department of Pharmaceutical Biomaterials, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Medical Biomaterials Research Center, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran.
  • Department of Clinical Pharmacy, Virtual University of Medical Sciences, Tehran, Iran.
  • Department of Medical Education, Virtual University of Medical Sciences, Tehran, Iran.
  • Australasian Nanoscience and Nanotechnology Initiative (ANNI), 8054 Monash University LPO, Clayton, 3168, Victoria, Australia.
  • School of Electrical and Computer Engineering, College of Engineering, University of Tehran, 14395-515 Tehran, Iran.

ORCID-Profile: Amir Farnudian-Habibi, Seyed Nasser Ostad, Mazda Rad-Malekshahi

Zitieren

APA

Farnudian-Habibi, A., Mirjani, M., Montazer, V., Aliebrahimi, S., Katouzian, I., Abdolhosseini, S., Rahmani, A., Keyvani, H., Ostad, S. N., & Rad-Malekshahi, M. (2022). Review on Approved and Inprogress COVID-19 Vaccines. Iranian Journal of Pharmaceutical Research, 21(1). https://doi.org/10.5812/ijpr.124228

Vancouver

Farnudian-Habibi A, Mirjani M, Montazer V, Aliebrahimi S, Katouzian I, Abdolhosseini S, et al. Review on Approved and Inprogress COVID-19 Vaccines. Iranian Journal of Pharmaceutical Research. 2022;21(1). doi:10.5812/ijpr.124228

BibTeX
@article{FarnudianHabibi2022,
  author = {Farnudian-Habibi, Amir and Mirjani, Mobina and Montazer, Vahideh and Aliebrahimi, Shima and Katouzian, Iman and Abdolhosseini, Saeed and Rahmani, Ali and Keyvani, Hossein and Ostad, Seyed Nasser and Rad-Malekshahi, Mazda},
  title = {Review on Approved and Inprogress COVID-19 Vaccines},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2022},
  volume = {21},
  number = {1},
  doi = {10.5812/ijpr.124228}
}
Kostenlos starten →